. . . . . . . "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]"@en . . . "2020-11-26T00:00:00Z"^^ . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . . . . . . . . . . . . . . . . . . "1280"^^ . . . . "A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer"@en . . . . . . . . . . . . . . . . . "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]"@en . . . . . . . . . . . . . . . . . . . . . "klinisch onderzoek"@nl . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . . . . . . . . . . . . . . . . . . . "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]"@en . . . . . . . "NCT02486718" . . . . . . . "18"^^ . . . . . . . . . . . . . . . . . . . . "2015-10-31T00:00:00Z"^^ .